Sarcoma News

Going through cancer during transitional adolescent and young adult years can present additional social, financial and mental health challenges that add to the stressors of diagnosis and treatment.

The FDA granted fast track designation to annamycin for the treatment of patients with lung metastases from soft tissue sarcoma, according to a press release from the agent’s manufacturer.

Sarcoma Alliance appointed William Tseng, MD, to its board of directors.

The FDA granted orphan drug designation to annamycin for the treatment of patients with soft tissue sarcoma, according to a manufacturer-issued press release.

A quarter of patients with unresectable or metastatic angiosarcoma responded to a combination of ipilimumab and nivolumab, according to results of an analysis presented at the virtual Society for Immunotherapy of Cancer Annual Meeting.

The FDA granted fast track and orphan drug designations to PTC596 for treatment of leiomyosarcoma, according to the agent’s manufacturer.

Letetresgene autoleucel demonstrated clinical activity among patients with advanced synovial sarcoma, according to final phase 1 study results presented at the virtual Society for Immunotherapy of Cancer Annual Meeting.

Letetresgene autoleucel demonstrated clinical activity among patients with advanced synovial sarcoma, according to final phase 1 study results presented at the virtual Society for Immunotherapy of Cancer Annual Meeting.

Cancer led to 4 million potential years of life lost in 2017 in the United States, with cancers occurring in younger patients accounting for a disproportionate amount of the burden, according to study results.

The FDA approved the FoundationOne CDx test to help identify certain neurotrophic receptor tyrosine kinase gene fusions in patients with solid tumors eligible for treatment with larotrectinib, according to a press release from the agency.